Clinical Trial Update: Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study evaluating RXI-109 to reduce progression of subretinal fibrosis in neovascular age-related macular degene…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization
• Subretinal Fibrosis
• Subretinal Scarring

Drugs mentioned

• RXI-109 (RXI-109)

Snippet

Sponsor: RXi Pharmaceuticals, Corp. | Conditions: Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization | Phase 1, Phase 2 | Status: UNKNOWN